MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment

Glycoconjugate Journal

Volumn 18, Issue 11-12, 2001, Pages 931-942

  Mukherjee, Pinku ^a   Ginardi, Amelia R ^a   Madsen, Cathy S ^a   Tinder, Teresa L ^a   Jacobs, Fred ^b   Parker, Joanne ^b   Agrawal, Babita ^b   Longenecker, B Michael ^b   Gendler, Sandra J ^a,c  

^a MAYO GRADUATE SCHOOL   (United States)

^b Biomira Inc   (Canada)

^c MAYO CLINIC   (United States)

Author keywords

Antigens peptides epitopes; CTL; Tolerance; Transgenic models; Tumor immunity

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MUCIN 1; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CANCER GROWTH; CELL KILLING; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOPTIVE TRANSFER; ANIMALS; CA-15-3 ANTIGEN; CANCER VACCINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; IMMUNE TOLERANCE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; PANCREATIC NEOPLASMS; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC; TRANSFORMING GROWTH FACTOR BETA; TUMOR ESCAPE; VACCINES, SYNTHETIC;

ANIMALIA;

EID: 0035526336     PISSN: 02820080     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022260711583     Document Type: Article

References (38)

1. Greenlee RT, Murray T, Bolden S, Wingo PA, Cancer statistics, CA Cancer J 50, 7-33 (2000).
2. Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, Gendler SJ, Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model, Cancer Res 58, 315-21 (1998).
3. Mukherjee P, Ginardi AR, Madsen CS, Sterner CJ, Adriance MC, Tevethia MJ, Gendler SJ, Mice with spontaneous pancreatic cancer naturally develop MUC1-specific CTLs that eradicate tumors when adoptively transferred, J Immunol 165, 3451-60 (2000).
4. Mukherjee P, Ginardi AR, Tinder TL, Sterner CJ, Gendler SJ, MUC1-specific CTLs eradicate tumors when adoptively transferred in vivo, Clin Can Res 7, 848s-55s (2001).
5. Ridge JP, Fuchs EJ, Matzinger P, Neonatal tolerance revisited: Turning on newborn T cells with dendritic cells, Science 271, 1723-6 (1996).
6. Sikut R, Sikut A, Zhang K, Baeckstrom D, Hansson GC, Reactivity of antibodies with highly glycosylated MUC1 mucins from colon carcinoma cells and bile, In Tumor Biology, edited by Rye PD, Price MR (S. Karger Medical and Scientific Publishers, 1998), pp. 122-6.
7. Papac RJ, Spontaneous regression of cancer, Cancer Treat Rev 22, 395-423 (1996).
8. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, et al., Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma, Nat Med 4, 321-7 (1998).
9. Lee KH, Wang E, Nielsen MB, Wunderlich J, Migueles S, Connors M, Steinberg SM, Rosenberg SA, Marincola FM, Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression, J Immunol 163, 6292-300 (1999).
10. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, et al., Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3, Int J Cancer 63, 883-5 (1995).
11. Monsurro V, Nielsen MB, Perez-Diez A, Dudley ME, Wang E, Rosenberg SA, Marincola FM, Kinetics of TCR use in response to repeated epitope-specific immunization, J Immunol 166, 5817-25 (2001).
12. Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T, King A, Ogg GS, Spiegel HM, Conlon C, Spina CA, et al., HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function, J Exp Med 192, 63-75 (2000).
13. Gamadia LE, Rentenaar RJ, Baars PA, Remmerswaal EB, Surachno S, Weel JF, Toebes M, Schumacher TN, ten Berge IJ, van Lier RA, Differentiation of cytomegalovirus-specific CD8(+) T cells in healthy and immunosuppressed virus carriers, Blood 98, 754-61 (2001).
14. Hamann D, Kostense S, Wolthers KC, Otto SA, Baars PA, Miedema F, van Lier RA, Evidence that human CD8+CD45RA+CD27-cells are induced by antigen and evolve through extensive rounds of division, Int Immunol 11, 1027-33 (1999).
15. Nagai M, Kubota R, Greten TF, Schneck JP, Leist TP, Jacobson S, Increased activated human T cell lymphotropic virus type I (HTLV-1) Tax11-19-specific memory and effector CD8+ cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis: Correlation with HTLV-I provirus load, J Infect Dis 183, 197-205 (2001).
16. Reilly RT, Gottlieb MB, Ercolini AM, Machiels JP, Kane CE, Okoye FI, Muller WJ, Dixon KH, Jaffee EM, HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice, Cancer Res 60, 3569-76 (2000).
17. Reilly RT, Machiels JP, Emens LA, Ercolini AM, Okoye FI, Lei RY, Weintraub D, Jaffee EM, The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors, Cancer Res 61, 880-3 (2001).
18. Nukina M, Mochida Y, Sakaguchi S, Sakaguchi G, Purification of Clostridium botulinum type G progenitor toxin, Zentralbl Bakteriol Mikrobiol Hyg [A] 268, 220-7 (1988).
19. Papiernik M, de Moraes ML, Pontoux C, Vasseur F, Penit C, Regulatory CD4 T cells: Expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency, Int Immunol 10, 371-8 (1998).
20. Read S, Mauze S, Asseman C, Bean A, Coffman R, Powrie F, CD38+CD45RB(low) CD4+ T cells: A population of T cells with immune regulatory activities in vitro, Eur J Immunol 28, 3435-47 (1998).
21. Smith H, Sakamoto Y, Kasai K, Tung KS, Effector and regulatory cells in autoimmune oophoritis elicited by neonatal thymectomy, J Immunol 147, 2928-33 (1991).
22. Suri-Payer E, Amar AZ, Thornton AM, Shevach EM, CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells, J Immunol 160, 1212-8 (1998).
23. van Stipdonk MJ, Lemmens EE, Schoenberger SP, Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation, Nat Immunol 2, 423-9 (2001).
24. Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR, Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help, J Exp Med 186, 65-70 (1997).
25. Husmann LA, Bevan MJ, Cooperation between helper T cells and cytotoxic T lymphocyte precursors, Ann NY Acad Sci 532, 158-69 (1988).
26. Akiba H, Oshima H, Takeda K, Atsuta M, Nakano H, Nakajima A, Nohara C, Yagita H, Okumura K, CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells, J Immunol 162, 7058-66 (1999).
27. Bansal-Pakala P, Jember AG, Croft M, Signaling through OX40 (CD134) breaks peripheral T-cell tolerance, Nat Med 7, 907-12 (2001).
28. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR, Help for cytotoxic-T-cell responses is mediated by CD40 signalling, Nature 393, 478-80 (1998).
29. Gramaglia I, Jember A, Pippig SD, Weinberg AD, Killeen N, Croft M, The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion, J Immunol 165, 3043-50 (2000).
30. Gramaglia I, Weinberg AD, Lemon M, Croft M, Ox-40 ligand: A potent costimulatory molecule for sustaining primary CD4 T cell responses, J Immunol 161, 6510-7 (1998).
31. Maxwell JR, Weinberg A, Prell RA, Vella AT, Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion, J Immunol 164, 107-12 (2000).
32. Tevethia MJ, Bonneau RH, Griffith JW, Mylin L, A simian virus 40 large T-antigen segment containing amino acids 1 to 127 and expressed under the control of the rat elastase-1 promoter produces pancreatic acinar carcinomas in transgenic mice, J Virol 71, 8157-66 (1997).
33. Silver LM, Laboratory mice, In Mouse Genetics Concepts and Applications (Oxford University Press, 1995), pp. 32-61.
34. Price MR, Rye PD, Petrakou E, Murray A, Brady K, Imai S, Haga S, Kiyozuka Y, Schol D, Meulenbroek MF, et al., Summary report on the ISOBM TD-4 Workshop: Analysis of 56 monoclonal antibodies against the MUC1 mucin (San Diego, California, 1996) Tumour Biol 19, 1-20 (1998).
35. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM, Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor, J Exp Med 176, 1693-702 (1992).
36. Guan HH, Budzynski W, Koganty RR, Krantz MJ, Reddish MA, Rogers JA, Longenecker BM, Samuel J, Liposomal formulations of synthetic MUC1 peptides: Effects of encapsulation versus surface display of peptides on immune responses, Bioconjug Chem 9, 451-8 (1998).
37. Boni LT, Batenjany MM, Neville ME, Guo Y, Xu L, Wu F, Mason JT, Robb RJ, Popescu MC, Interleukin-2-induced small unilamellar vesicle coalescence, Biochim Biophys Acta 1514, 127-38 (2001).
38. Maeda H, Tsuru S, Shiraishi A, Improvement of macrophage dysfunction by administration of anti-transforming growth factor-beta antibody in EL4-bearing hosts, Jpn J Cancer Res 85, 1137-43 (1994).